Trials / Unknown
UnknownNCT02956551
Personalized DC Vaccine for Lung Cancer
Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.
Detailed description
Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | DC vaccine | subcutaneous administration |
Timeline
- Start date
- 2016-11-30
- Primary completion
- 2019-12-31
- Completion
- 2020-06-01
- First posted
- 2016-11-07
- Last updated
- 2018-05-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02956551. Inclusion in this directory is not an endorsement.